Abstract:An artificial nano‐protein (ANP) is developed by fusing human serum albumin with a degrading peptide and the porphyrin‐photosensitizer verteporfin. ANP is demonstrated effective degradation of MDM2/MDMX proteins in the ubiquitin degradation pathway, leading to reactivation of the p53 pathway. This subsequently sensitizes verteporfin‐photodynamic therapy‐mediated cell death through mitochondrial damage, offering a new strategy for safe and effective treatment of retinoblastoma. The treatment of retinoblastoma (RB), a formidable eye cancer that affects infants and children, is not only aimed at saving lives but at preserving ocular function, maintaining optimal visual acuity, and enhancing the overall quality of life. Photodynamic therapy has already been established as a secure and dependable therapeutic modality for the treatment of ocular diseases that effectively preserves ocular function; however, it fails to provide satisfactory outcomes against RB. To address this formidable challenge, groundbreaking advancement is aspired by delving into the genetic characteristics of RB, which initially involves the wild‐type p53 pathway but is subsequently suppressed by MDM2 and MDMX. In this study, an artificial nanoprotein (ANP) is developed through the fusion of human serum albumin with a potent MDM2/MDMX degrading peptide and the porphyrin‐photosensitizer verteporfin (VP). ANP effectively dismantles MDM2/MDMX proteins within the ubiquitin‐proteasome degradation pathway and triggers VP‐PDT‐mediated cell death through mitochondrial impairment. Remarkably, ANP exhibited remarkable therapeutic efficacy in both subcutaneous and in situ RB mouse models, while maintaining a highly favorable biosafety profile. Collectively, ANP not only provides compelling evidence for sensitizing photodynamic RB therapy by reactivating p53, but also serves as an exceptionally potent photosensitizer with promising potential for clinical translation in RB treatment.

A Novel Cell-Permeable RDP-p53 Fusion Protein for Specific Inhibition on the Growth of Cancerous Neural Cells

Interpreting the Therapeutic Efficiency of Multifunctional Hybrid Nanostructure Against Glioblastoma

Expression and Immunogenicity Analysis of p53 Protein Fused with a New Cell-Penetrating Peptide

Inhibition of Cell Proliferation, Migration and Invasion by A Glioma-Targeted Fusion Protein Combining the P53 C Terminus and Mdm2-Binding Domain

Glioma Targeting Peptide in Combination with the P53 C Terminus Inhibits Glioma Cell Proliferation in Vitro

Efficient P53 Activation and Apoptosis Induction of MDM2/MDMX Inhibitory Protein, a Recombinant Cell-Permeable Fusion Protein, in P53- Breast Cancer Cells.

Cellular Uptake Mechanism and Therapeutic Utility of a Novel Peptide in Targeted-Delivery of Proteins into Neuronal Cells

Anti-tumor Efficacy of P53 with 9R Cell-Penetrating Peptides

RNA Interference Targeting Mutant P53 Inhibits Growth and Induces Apoptosis in DU145 Human Prostate Cancer Cells

Targeted Delivery Of A Novel Palmitylated D-Peptide For Antiglioblastoma Molecular Therapy

Design and screening of a novel neuropilin-1 targeted penetrating peptide for anti-angiogenic therapy in glioma

Designed novel nuclear localizing anticancer peptide targets p53 negative regulator MDM2 protein

A New Nrf2 Inhibitor Enhances Chemotherapeutic Effects in Glioblastoma Cells Carrying p53 Mutations

A novel approach to glioma therapy using an oncolytic adenovirus with two specific promoters.

Inhibiting Bladder Tumor Growth with a Cell Penetrating R11 Peptide Derived from the P53 C-terminus.

Resurrecting p53 by an Artificial Nano‐Protein for Potent Photodynamic Retinoblastoma Therapy

Recombinant GnRH-p53 protein sensitizes breast cancer cells to 5-fluorouracil-induced apoptosis in vitro and in vivo

Induction of P53 Expression and Apoptosis by a Recombinant Dual-Target MDM2/MDMX Inhibitory Protein in Wild-Type P53 Breast Cancer Cells.

Effects of RDP-p53 Fusion Protein on Inflammatory Cytokine of Mice

Development of P53 Protein Transduction Therapy Using Membrane-Permeable Peptides and the Application to Oral Cancer Cells.

Targeted Gene Delivery to Glioblastoma Using a C-end Rule RGERPPR Peptide-Functionalised Polyethylenimine Complex